Abstract

To study the effectiveness and safety of targeted therapy in combination with immunotherapy for neoadjuvant treatment of advanced hepatocellular carcinoma. 65 advanced hepatocellular carcinoma patients who underwent hepatectomy in our hospital from January 2019 to December 2021 were retrospectively analyzed. Among them, 45 patients in the control group underwent conventional surgery and 20 patients in the study group got neoadjuvant therapy. The short-term curative effect of the patients in the study group was assessed. The intraoperative blood loss, intraoperative blood transfusion volume, postoperative hospital stays, postoperative blood transfusion volume and operation time were collected from the two groups of patients and the postoperative complications were correlated between the two groups. The overall survival and postoperative recurrence of the patients were obtained through followup. The 3 mo overall response rate of patients in the study group who underwent apatinib combined with camrelizumab was 35.00 % and the disease control rate was 75.00 %. There were no notable variations between the two groups in operation time, intraoperative blood loss, postoperative blood transfusion volume, intraoperative blood transfusion volume and postoperative hospital stays (all p>0.05). The rate of postoperative complications did not significantly differ between the two groups (p>0.05). The follow-up results showed that the recurrence time was remarkably later than that of the control group (p=0.023) and the survival time of the control group (p=0.041) was remarkably shorter than that of the study group. Immune checkpoint inhibitors expressed by programmed cell death 1/programmed cell death ligand 1 monoclonal antibody and anti-antigenic targeted drugs combined with neoadjuvant therapy have good safety for patients with resectable hepatocellular carcinoma, can improve the prognosis of patients, prolong the patient's survival time, toxic and side effects are acceptable.